Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 146 recruiting now early-phase tilt #12 of 28,707 conditions

Lung Cancer: early-phase trial registry

146 of 430 indexed Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #12 of 28,707 conditions by registered trial count.

430 US clinical trials · 146 currently recruiting · #12 of 28,707 conditions by registered trial count

Lung Cancer: 430 US clinical trials tracked, 146 recruiting.

Lung Cancer is the subject of 430 registered US clinical trials on ClinicalTrials.gov, 146 of them currently open to new participants. 23 are in Phase 3-4 (later-stage) and 181 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 36 of these trials.

Enrollment posture brief

Registry condition lung-cancer

OPEN 146 | RECR 34% | LATE 23 | EARLY 181 | RANK #12 | SPON 36

Nearest open-share peer: Solid Tumors (34% recruiting · 127 trials)

Stroke47.8%Non-Small Cell Lung Cancer45.3%Heart Failure41.1%Multiple Myeloma37.9%Lung Cancer (this)34%
Open-enrollment share among volume-matched conditions near Lung Cancer

Lung Cancer lists 146 open slots (34% of 430 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lung Cancer is recruiting below its size-band peers.

    146 of 430 indexed trials (34%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Lung Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 36 of 430 trials (8.4%). 179 distinct sponsors appear on at least one study for this condition label.

  3. Typical Lung Cancer enrolment sits around 89 participants.

    Median target enrolment is 89 among the 410 trials that report a genuine target (sentinel values excluded). 212 of those (51.7%) plan for fewer than 100 participants.

  4. Lung Cancer research is mostly interventional.

    321 interventional and 109 observational studies make up this index (74.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 185Phase 296Phase 322Phase 41

Open and recent trials

430 total, page 8 of 9

COMPLETED NA 35 participants

Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer

Ronald McGarry

NCT01657617

COMPLETED 33 participants

Functional Imaging in Lung SBRT

University of Michigan Rogel Cancer Center

NCT03121300

COMPLETED NA 32 participants

Improving Management of Breathlessness in Patients With Lung Cancer

Massachusetts General Hospital

NCT01937637

COMPLETED Phase 2 32 participants

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer

Edward Hirschowitz

NCT00103116

COMPLETED NA 31 participants

A Phase I Study of iPS Cell Generation From Patients With COPD

Mayo Clinic

NCT01860898

COMPLETED NA 30 participants

Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness

Massachusetts General Hospital

NCT02594696

COMPLETED Phase 2 30 participants

Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer

Medstar Health Research Institute

NCT00006469

COMPLETED Phase 1 30 participants

Chemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

California Cancer Consortium

NCT00033410

COMPLETED Phase 2 30 participants

Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The University of Texas Medical Branch, Galveston

NCT00075426

COMPLETED 30 participants

Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease

Massachusetts General Hospital

NCT01396603

COMPLETED Phase 1 30 participants

Vinorelbine and XR9576 to Treat Cancer

National Cancer Institute (NCI)

NCT00001944

COMPLETED Phase 2 30 participants

Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Jonsson Comprehensive Cancer Center

NCT00024076

COMPLETED Phase 1 30 participants

G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer

G1 Therapeutics

NCT03455829

COMPLETED 29 participants

Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy

UNC Lineberger Comprehensive Cancer Center

NCT01789983

COMPLETED Phase 2 29 participants

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

Fox Chase Cancer Center

NCT00021333

COMPLETED 25 participants

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Vanderbilt-Ingram Cancer Center

NCT00897793

COMPLETED Phase 3 25 participants

Megestrol in Treating Patients Who Are Undergoing Radiation Therapy for Lung Cancer

Wake Forest University Health Sciences

NCT00031785

COMPLETED Phase 2 24 participants

A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies

OncoNano Medicine

NCT05048082

COMPLETED Phase 1 24 participants

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Memorial Sloan Kettering Cancer Center

NCT03076164

COMPLETED Phase 2 24 participants

Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors

Georgetown University

NCT00003125

COMPLETED NA 24 participants

Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy

Vanderbilt-Ingram Cancer Center

NCT02324881

COMPLETED Phase 1 23 participants

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Novita Pharmaceuticals

NCT03199586

COMPLETED Phase 1 23 participants

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

NCT00533585

COMPLETED Phase 1 22 participants

Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib

Memorial Sloan Kettering Cancer Center

NCT02155465

COMPLETED Phase 3 22 participants

Bintrafusp Alfa Program Rollover Study

EMD Serono Research & Development Institute

NCT05061823

COMPLETED Phase 1 22 participants

Lapatinib and Cetuximab in Patients With Solid Tumors

Georgetown University

NCT01184482

COMPLETED Phase 2 21 participants

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Alliance for Clinical Trials in Oncology

NCT00005850

COMPLETED NA 21 participants

Project HEALS (Helping and Empowering pAtients for Living a Life Smoke-free

H. Lee Moffitt Cancer Center and Research Institute

NCT05362318

COMPLETED Phase 1 20 participants

Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer

National Cancer Institute (NCI)

NCT00002537

COMPLETED Phase 2 20 participants

Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma

Swedish Medical Center

NCT00430261

COMPLETED Phase 1 20 participants

Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma

Roswell Park Cancer Institute

NCT00003974

COMPLETED Phase 1 20 participants

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

M.D. Anderson Cancer Center

NCT00346801

COMPLETED NA 19 participants

Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers

Dartmouth-Hitchcock Medical Center

NCT02648178

COMPLETED 18 participants

Risk Stratification for Patients With Hospital-diagnosed Advanced Lung Cancer

UNC Lineberger Comprehensive Cancer Center

NCT05722847

COMPLETED Phase 1 18 participants

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Poniard Pharmaceuticals

NCT00465725

COMPLETED Phase 3 17 participants

Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Case Comprehensive Cancer Center

NCT00074204

COMPLETED Phase 1 17 participants

Gold Sodium Thiomalate in Treating Patients With Advanced Non-Small Cell Lung Cancer

Mayo Clinic

NCT00575393

COMPLETED Phase 1 17 participants

Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer

Stanford University

NCT00946673

COMPLETED Phase 1 17 participants

Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer

Roswell Park Cancer Institute

NCT00526461

COMPLETED Phase 2 16 participants

Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Vanderbilt-Ingram Cancer Center

NCT00416650

COMPLETED Phase 1 16 participants

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT00703638

COMPLETED Phase 2 15 participants

Bryostatin 1 Plus Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

University of Chicago

NCT00005849

COMPLETED Phase 1 15 participants

Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

SCRI Development Innovations

NCT00315861

COMPLETED Phase 2 14 participants

Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Wake Forest University Health Sciences

NCT00025272

COMPLETED Phase 1 14 participants

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Syndax Pharmaceuticals

NCT01594398

COMPLETED NA 14 participants

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Milton S. Hershey Medical Center

NCT06028152

COMPLETED Phase 2 13 participants

Sunitinib in Never-Smokers With Lung Adenocarcinoma

Dana-Farber Cancer Institute

NCT01829217

COMPLETED Phase 1 12 participants

A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA®) in the Treatment of Non-Small Cell Lung Cancer

Stanford University

NCT00238628

COMPLETED 12 participants

Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR)

University of Texas Southwestern Medical Center

NCT05459311

COMPLETED NA 12 participants

Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer

Dr Thomas DiPetrillo

NCT01656460

← Previous Page 8 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 85
Phase 2 96
Phase 3 22
Phase 4 1

Named interventions

Most-linked intervention names on Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

paclitaxel Drug
20 trials
carboplatin Drug
20 trials
Carboplatin Drug
17 trials
radiation therapy Radiation
12 trials
Pemetrexed Drug
11 trials
Cisplatin Drug
10 trials
gemcitabine hydrochloride Drug
8 trials
cisplatin Drug
8 trials

US sites by state

Facility locations filed on Lung Cancer trials. A trial with sites in several states counts in each.

California 95 trials
New York 93 trials
Florida 70 trials
Texas 63 trials
Massachusetts 62 trials
Pennsylvania 51 trials
Illinois 50 trials
Ohio 43 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lung Cancer page

430 registered trials, 146 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lung Cancer condition card totals 430 registered trials; most-linked intervention paclitaxel; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.